Agilent Technologies
About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Employees: 17,900
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
50% more call options, than puts
Call options by funds: $164M | Put options by funds: $109M
49% more first-time investments, than exits
New positions opened: 134 | Existing positions closed: 90
2% more funds holding
Funds holding: 1,034 [Q3] → 1,058 (+24) [Q4]
2.09% more ownership
Funds ownership: 86.18% [Q3] → 88.27% (+2.09%) [Q4]
4% less repeat investments, than reductions
Existing positions increased: 363 | Existing positions reduced: 377
8% less capital invested
Capital invested by funds: $36.6B [Q3] → $33.9B (-$2.79B) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 12 [Q3] → 8 (-4) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$115
7%
upside
Avg. target
$131
22%
upside
High target
$159
48%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Jefferies Brandon Couillard 8% 1-year accuracy 2 / 25 met price target | 8%upside $116 | Hold Maintained | 21 Apr 2025 |
Wells Fargo Brandon Couillard 8% 1-year accuracy 2 / 25 met price target | 25%upside $135 | Overweight Maintained | 17 Apr 2025 |
Barclays Luke Sergott 31% 1-year accuracy 18 / 59 met price target | 7%upside $115 | Equal-Weight Maintained | 10 Apr 2025 |
Baird Catherine Schulte 5% 1-year accuracy 1 / 19 met price target | 48%upside $159 | Outperform Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 7 articles about A published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Positive
Seeking Alpha
6 days ago
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures.
Neutral
GlobeNewsWire
6 days ago
Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission
LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture (“JV”) between Standard Lithium Ltd.
Neutral
Business Wire
6 days ago
Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions t.
Neutral
Business Wire
1 week ago
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced.
Positive
Zacks Investment Research
2 weeks ago
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Positive
Seeking Alpha
3 weeks ago
Fear Creates Fortunes: Grab These 7 Blue-Chip Bargains Today
Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-time economic indicators show GDP growth of more than 2%, despite widespread recession fears, highlighting a disconnect between sentiment and fundamentals. Inflation truth vs. hype: Real-time data shows inflation is falling, contradicting consumer fears and demonstrating that stagflation panic may be premature.
Neutral
Business Wire
1 month ago
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a.
Neutral
Business Wire
1 month ago
CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will.
Neutral
Business Wire
1 month ago
Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for dia.
Charts implemented using Lightweight Charts™